All doses of the diabetes and weight management injectable tirzepatide (Mounjaro, Zepbound) were taken off the FDA's shortage ...

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...

With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...

Nearly 250,000 people in England could access a weight loss injection on the NHS. Tirzepatide is prescribed for type 2 diabetes, but has been shown in clinical trials to be effective for weight loss.

The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...